{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:01:42Z","timestamp":1792004502425,"version":"4.4.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T00:00:00Z","timestamp":1552608000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"research funds from the Division of Rheumatology at the University of Alabama at Birmingham","award":["No number"],"award-info":[{"award-number":["No number"]}]},{"name":"resources and use of facilities at the Birmingham VA Medical Center, Birmingham, Alabama, USA","award":["No number"],"award-info":[{"award-number":["No number"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12882-019-1274-5","type":"journal-article","created":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T16:06:01Z","timestamp":1552665961000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Gout is associated with a higher risk of chronic renal disease in older adults: a retrospective cohort study of U.S. Medicare population"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3485-0006","authenticated-orcid":false,"given":"Jasvinder A.","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Cleveland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,15]]},"reference":[{"key":"1274_CR1","unstructured":"World Kidney Day: Chronic Kidney Disease. 2015; \n                    http:\/\/www.worldkidneyday.org\/faqs\/chronic-kidney-disease\/\n                    \n                  . Accessed 5 Mar 2019."},{"issue":"9888","key":"1274_CR2","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S0140-6736(13)60687-X","volume":"382","author":"V Jha","year":"2013","unstructured":"Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, Saran R, Wang AY, Yang CW. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382(9888):260\u201372.","journal-title":"Lancet"},{"issue":"9","key":"1274_CR3","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1093\/rheumatology\/keh640","volume":"44","author":"N Dalbeth","year":"2005","unstructured":"Dalbeth N, Haskard DO. Mechanisms of inflammation in gout. Rheumatology (Oxford). 2005;44(9):1090\u20136.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"1274_CR4","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/1471-2369-15-122","volume":"15","author":"L Li","year":"2014","unstructured":"Li L, Yang C, Zhao Y, Zeng X, Liu F, Fu P. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease? A systematic review and meta-analysis based on observational cohort studies. BMC Nephrol. 2014;15(1):122.","journal-title":"BMC Nephrol"},{"issue":"7","key":"1274_CR5","first-page":"555","volume":"50","author":"YL Li","year":"2011","unstructured":"Li YL, Wang L, Li J, Huang Y, Yuan WM. The correlation between uric acid and the incidence and prognosis of kidney diseases: a systematic review and meta-analysis of cohort studies. Zhonghua Nei Ke Za Zhi. 2011;50(7):555\u201361.","journal-title":"Zhonghua Nei Ke Za Zhi"},{"issue":"12","key":"1274_CR6","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1097\/01.ASN.0000034910.58454.FD","volume":"13","author":"DH Kang","year":"2002","unstructured":"Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, Truong L, Harris R, Johnson RJ. A role for uric acid in the progression of renal disease. J Am Soc Nephrol. 2002;13(12):2888\u201397.","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"1274_CR7","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/0895-4356(93)90103-8","volume":"46","author":"PS Romano","year":"1993","unstructured":"Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993;46(10):1075\u20139; discussion 1081-1090.","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"1274_CR8","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1053\/j.ajkd.2008.07.055","volume":"53","author":"AJ Collins","year":"2009","unstructured":"Collins AJ, Chen SC, Gilbertson DT, Foley RN. CKD surveillance using administrative data: impact on the health care system. Am J Kidney Dis. 2009;53(3 Suppl 3):S27\u201336.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"1274_CR9","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","volume":"45","author":"RA Deyo","year":"1992","unstructured":"Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613\u20139.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"1274_CR10","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/00005650-199401000-00006","volume":"32","author":"PS Romano","year":"1994","unstructured":"Romano PS, Mark DH. Bias in the coding of hospital discharge data and its implications for quality assessment. Med Care. 1994;32(1):81\u201390.","journal-title":"Med Care"},{"issue":"1","key":"1274_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1053\/j.ajkd.2010.08.031","volume":"57","author":"ME Vlasschaert","year":"2011","unstructured":"Vlasschaert ME, Bejaimal SA, Hackam DG, Quinn R, Cuerden MS, Oliver MJ, Iansavichus A, Sultan N, Mills A, Garg AX. Validity of administrative database coding for kidney disease: a systematic review. Am J Kidney Dis. 2011;57(1):29\u201343.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"1274_CR12","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1002\/art.22767","volume":"57","author":"JA Singh","year":"2007","unstructured":"Singh JA, Hodges JS, Toscano JP, Asch SM. Quality of care for gout in the US needs improvement. Arthritis Rheum. 2007;57(5):822\u20139.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"1274_CR13","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.biocel.2013.02.009","volume":"45","author":"K Chen","year":"2013","unstructured":"Chen K, Zhang J, Zhang W, Zhang J, Yang J, Li K, He Y. ATP-P2X4 signaling mediates NLRP3 inflammasome activation: a novel pathway of diabetic nephropathy. Int J Biochem Cell Biol. 2013;45(5):932\u201343.","journal-title":"Int J Biochem Cell Biol"},{"issue":"1","key":"1274_CR14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2147\/IJICMR.S10111","volume":"2","author":"LM Ortega","year":"2010","unstructured":"Ortega LM, Fornoni A. Role of cytokines in the pathogenesis of acute and chronic kidney disease, glomerulonephritis, and end-stage kidney disease. Int J Interfer Cytok Mediat Res. 2010;2(1):49\u201362.","journal-title":"Int J Interfer Cytok Mediat Res"},{"issue":"10","key":"1274_CR15","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1681\/ASN.2010020143","volume":"21","author":"A Vilaysane","year":"2010","unstructured":"Vilaysane A, Chun J, Seamone ME, Wang W, Chin R, Hirota S, Li Y, Clark SA, Tschopp J, Trpkov K, et al. The NLRP3 inflammasome promotes renal inflammation and contributes to CKD. J Am Soc Nephrol. 2010;21(10):1732\u201344.","journal-title":"J Am Soc Nephrol"},{"issue":"7081","key":"1274_CR16","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nature04516","volume":"440","author":"F Martinon","year":"2006","unstructured":"Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440(7081):237\u201341.","journal-title":"Nature"},{"issue":"8","key":"1274_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0072344","volume":"8","author":"L Fang","year":"2013","unstructured":"Fang L, Xie D, Wu X, Cao H, Su W, Yang J. Involvement of endoplasmic reticulum stress in albuminuria induced inflammasome activation in renal proximal tubular cells. PLoS One. 2013;8(8):e72344.","journal-title":"PLoS One"},{"issue":"2","key":"1274_CR18","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/eci.12392","volume":"45","author":"S Martin-Rodriguez","year":"2015","unstructured":"Martin-Rodriguez S, Caballo C, Gutierrez G, Vera M, Cruzado JM, Cases A, Escolar G, Diaz-Ricart M. TLR4 and NALP3 inflammasome in the development of endothelial dysfunction in uraemia. Eur J Clin Investig. 2015;45(2):160\u20139.","journal-title":"Eur J Clin Investig"},{"issue":"2","key":"1274_CR19","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1159\/000058399","volume":"91","author":"K Matsumoto","year":"2002","unstructured":"Matsumoto K, Kanmatsuse K. Increased urinary excretion of interleukin-17 in nephrotic patients. Nephron. 2002;91(2):243\u20139.","journal-title":"Nephron"},{"issue":"5","key":"1274_CR20","doi-asserted-by":"publisher","first-page":"327","DOI":"10.5414\/CNP60327","volume":"60","author":"G Lonnemann","year":"2003","unstructured":"Lonnemann G, Novick D, Rubinstein M, Dinarello CA. Interleukin-18, interleukin-18 binding protein and impaired production of interferon-gamma in chronic renal failure. Clin Nephrol. 2003;60(5):327\u201334.","journal-title":"Clin Nephrol"},{"key":"1274_CR21","doi-asserted-by":"crossref","unstructured":"Johnson RJ, Bakris GL, Borghi C, Chonchol MB, Feldman D, Lanaspa MA, Merriman TR, Moe OW, Mount DB, Sanchez Lozada LG, et al. Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of a scientific workshop organized by the National Kidney Foundation. Am J Kidney Dis. 2018;71(6):851-65.","DOI":"10.1053\/j.ajkd.2017.12.009"},{"key":"1274_CR22","doi-asserted-by":"crossref","unstructured":"Jing J, Kielstein JT, Schultheiss UT, Sitter T, Titze SI, Schaeffner ES, McAdams-DeMarco M, Kronenberg F, Eckardt KU, Kottgen A, et al. Prevalence and correlates of gout in a large cohort of patients with chronic kidney disease: the German chronic kidney disease (GCKD) study. Nephrol Dial Transplant. 2014;30(4):613-21.","DOI":"10.1093\/ndt\/gfu352"},{"issue":"6","key":"1274_CR23","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.semarthrit.2012.09.009","volume":"42","author":"SP Juraschek","year":"2013","unstructured":"Juraschek SP, Kovell LC, Miller ER 3rd, Gelber AC. Association of kidney disease with prevalent gout in the United States in 1988-1994 and 2007-2010. Semin Arthritis Rheum. 2013;42(6):551\u201361.","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"1274_CR24","doi-asserted-by":"publisher","first-page":"F991","DOI":"10.1152\/ajprenal.00283.2001","volume":"282","author":"M Mazzali","year":"2002","unstructured":"Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, Kang DH, Gordon KL, Watanabe S, Nakagawa T, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol. 2002;282(6):F991\u20137.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"1274_CR25","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1159\/000066303","volume":"23","author":"T Nakagawa","year":"2003","unstructured":"Nakagawa T, Mazzali M, Kang DH, Kanellis J, Watanabe S, Sanchez-Lozada LG, Rodriguez-Iturbe B, Herrera-Acosta J, Johnson RJ. Hyperuricemia causes glomerular hypertrophy in the rat. Am J Nephrol. 2003;23(1):2\u20137.","journal-title":"Am J Nephrol"},{"issue":"5","key":"1274_CR26","doi-asserted-by":"publisher","first-page":"F1105","DOI":"10.1152\/ajprenal.00170.2002","volume":"283","author":"LG Sanchez-Lozada","year":"2002","unstructured":"Sanchez-Lozada LG, Tapia E, Avila-Casado C, Soto V, Franco M, Santamaria J, Nakagawa T, Rodriguez-Iturbe B, Johnson RJ, Herrera-Acosta J. Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol Renal Physiol. 2002;283(5):F1105\u201310.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"6","key":"1274_CR27","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/MAJ.0b013e3181db6e16","volume":"339","author":"HY Chang","year":"2010","unstructured":"Chang HY, Tung CW, Lee PH, Lei CC, Hsu YC, Chang HH, Yang HF, Lu LC, Jong MC, Chen CY, et al. Hyperuricemia as an independent risk factor of chronic kidney disease in middle-aged and elderly population. Am J Med Sci. 2010;339(6):509\u201315.","journal-title":"Am J Med Sci"},{"issue":"12","key":"1274_CR28","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1681\/ASN.2008010080","volume":"19","author":"RP Obermayr","year":"2008","unstructured":"Obermayr RP, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R, Klauser-Braun R. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol. 2008;19(12):2407\u201313.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"1274_CR29","doi-asserted-by":"publisher","first-page":"280","DOI":"10.4103\/0971-4065.114499","volume":"23","author":"BH Pai","year":"2013","unstructured":"Pai BH, Swarnalatha G, Ram R, Dakshinamurty KV. Allopurinol for prevention of progression of kidney disease with hyperuricemia. Indian J Nephrol. 2013;23(4):280\u20136.","journal-title":"Indian J Nephrol"},{"issue":"2","key":"1274_CR30","doi-asserted-by":"publisher","first-page":"316","DOI":"10.4103\/1319-2442.128520","volume":"25","author":"S Sezer","year":"2014","unstructured":"Sezer S, Karakan S, Atesagaoglu B, Acar FN. Allopurinol reduces cardiovascular risks and improves renal function in pre-dialysis chronic kidney disease patients with hyperuricemia. Saudi J Kidney Dis Transpl. 2014;25(2):316\u201320.","journal-title":"Saudi J Kidney Dis Transpl"},{"issue":"5","key":"1274_CR31","doi-asserted-by":"publisher","first-page":"955","DOI":"10.3899\/jrheum.131159","volume":"41","author":"GD Levy","year":"2014","unstructured":"Levy GD, Rashid N, Niu F, Cheetham TC. Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia. J Rheumatol. 2014;41(5):955\u201362.","journal-title":"J Rheumatol"},{"issue":"5","key":"1274_CR32","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0002-9610(88)80196-X","volume":"156","author":"PF Gores","year":"1988","unstructured":"Gores PF, Fryd DS, Sutherland DE, Najarian JS, Simmons RL. Hyperuricemia after renal transplantation. Am J Surg. 1988;156(5):397\u2013400.","journal-title":"Am J Surg"},{"issue":"2","key":"1274_CR33","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1053\/j.ajkd.2007.05.013","volume":"50","author":"M Chonchol","year":"2007","unstructured":"Chonchol M, Shlipak MG, Katz R, Sarnak MJ, Newman AB, Siscovick DS, Kestenbaum B, Carney JK, Fried LF. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis. 2007;50(2):239\u201347.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"1274_CR34","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1053\/j.ajkd.2008.12.021","volume":"53","author":"M Madero","year":"2009","unstructured":"Madero M, Sarnak MJ, Wang X, Greene T, Beck GJ, Kusek JW, Collins AJ, Levey AS, Menon V. Uric acid and long-term outcomes in CKD. Am J Kidney Dis. 2009;53(5):796\u2013803.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"1274_CR35","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/0002-9343(79)90076-7","volume":"67","author":"WJ Fessel","year":"1979","unstructured":"Fessel WJ. Renal outcomes of gout and hyperuricemia. Am J Med. 1979;67(1):74\u201382.","journal-title":"Am J Med"},{"issue":"1","key":"1274_CR36","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13075-015-0624-3","volume":"17","author":"JA Singh","year":"2015","unstructured":"Singh JA, Akhras KS, Shiozawa A. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort. Arthritis Res Ther. 2015;17(1):120.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"1274_CR37","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1053\/j.ajkd.2015.05.017","volume":"66","author":"D Sircar","year":"2015","unstructured":"Sircar D, Chatterjee S, Waikhom R, Golay V, Raychaudhury A, Chatterjee S, Pandey R. Efficacy of Febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: a 6-month, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis. 2015;66(6):945\u201350.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"1274_CR38","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1093\/ndt\/gft378","volume":"29","author":"B Bose","year":"2014","unstructured":"Bose B, Badve SV, Hiremath SS, Boudville N, Brown FG, Cass A, de Zoysa JR, Fassett RG, Faull R, Harris DC, et al. Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2014;29(2):406\u201313.","journal-title":"Nephrol Dial Transplant"},{"key":"1274_CR39","unstructured":"Singh JA, Yu S. Are allopurinol dose and duration of use nephroprotective in the elderly? A Medicare claims study of allopurinol use and incident renal failure. Ann Rheum Dis. 2016;76(1):133-9."},{"issue":"2","key":"1274_CR40","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1681\/ASN.2004030203","volume":"16","author":"RN Foley","year":"2005","unstructured":"Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, Collins AJ. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005;16(2):489\u201395.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"1274_CR41","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1053\/j.ajkd.2005.04.029","volume":"46","author":"WC Winkelmayer","year":"2005","unstructured":"Winkelmayer WC, Schneeweiss S, Mogun H, Patrick AR, Avorn J, Solomon DH. Identification of individuals with CKD from Medicare claims data: a validation study. Am J Kidney Dis. 2005;46(2):225\u201332.","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"1274_CR42","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1097\/01.ASN.0000129982.10611.4C","volume":"15","author":"WM McClellan","year":"2004","unstructured":"McClellan WM, Langston RD, Presley R. Medicare patients with cardiovascular disease have a high prevalence of chronic kidney disease and a high rate of progression to end-stage renal disease. J Am Soc Nephrol. 2004;15(7):1912\u20139.","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl 7","key":"1274_CR43","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/ndt\/16.suppl_7.57","volume":"16","author":"A Levin","year":"2001","unstructured":"Levin A. Identification of patients and risk factors in chronic kidney disease--evaluating risk factors and therapeutic strategies. Nephrol Dial Transplant. 2001;16(Suppl 7):57\u201360.","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"1274_CR44","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1097\/01.ASN.0000095249.99803.85","volume":"14","author":"MK Haroun","year":"2003","unstructured":"Haroun MK, Jaar BG, Hoffman SC, Comstock GW, Klag MJ, Coresh J. Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland. J Am Soc Nephrol. 2003;14(11):2934\u201341.","journal-title":"J Am Soc Nephrol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1274-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-019-1274-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1274-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,14]],"date-time":"2020-03-14T00:05:55Z","timestamp":1584144355000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-019-1274-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,15]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1274"],"URL":"https:\/\/doi.org\/10.1186\/s12882-019-1274-5","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,15]]},"assertion":[{"value":"20 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The University of Alabama at Birmingham\u2019s Institutional Review Board approved this study and all investigations were conducted in conformity with ethical principles of research. The IRB waived the need for an informed consent for this database study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JAS has received research grants from Takeda and Savient and consultant fees from Savient, Takeda, Regeneron, Merz, Iroko, Bioiberica, Fidia, Crealta\/Horizon and Allergan pharmaceuticals, WebMD, UBM LLC, National Institute of Health and the American College of Rheumatology. JAS owns stock options in Amarin pharmaceuticals and Viking therapeutics.\u00a0JAS serves as the principal investigator for an investigator-initiated study funded by Horizon pharmaceuticals through a grant to DINORA, Inc., a 501 (c)(3) entity. JAS is a member of the executive of OMERACT, an organization that develops outcome measures in rheumatology and receives arms-length funding from 36 companies; a member of the American College of Rheumatology\u2019s (ACR) Annual Meeting Planning Committee (AMPC); Chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. JAS is the editor and Director of the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis. JDC has no relevant financial conflicts. There are no non-financial competing interests for either author.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"93"}}